Galmed Pharmaceuticals Company Profile (NASDAQ:GLMD)

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate, aramchol, is a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis (NASH). The Company's Aramchol is a conjugate of cholic acid and arachidic acid, which is a member of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis (NASH). Aramchol is in Phase IIb clinical trials.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: GLMD
CUSIP:

Key Metrics:

Previous Close: $4.91
50 Day Moving Average: $4.09
200 Day Moving Average: $4.69
52-Week Range: $3.50 - $10.20
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -3.90
P/E Growth: 0.00
Market Cap: $54.51M
Outstanding Shares: 11,102,000
Beta: 2.22

Profitability:

Return on Equity: -71.48%
Return on Assets: -62.73%

Debt:

Current Ratio: 5.12%
Quick Ratio: 5.12%

Additional Links:

Companies Related to Galmed Pharmaceuticals:

Consensus Ratings for Galmed Pharmaceuticals (NASDAQ:GLMD) (?)

Ratings Breakdown:	4 Buy Ratings
Consensus Rating:	Buy (Score: 3.00)
Consensus Price Target:	$14.25 (190.22% upside)

Analysts' Ratings History for Galmed Pharmaceuticals (NASDAQ:GLMD)

Show:

Date	Firm	Action	Rating	Price Target
8/5/2016	FBR & Co	Set Price Target	Buy	$20.00
8/1/2016	Maxim Group	Reiterated Rating	Buy	$24.00 -> $9.00
7/6/2016	Roth Capital	Reiterated Rating	Buy	$6.00
6/30/2016	HC Wainwright	Reiterated Rating	Buy
8/19/2015	MLV & Co.	Reiterated Rating	Buy	$24.00
8/14/2015	SunTrust Banks Inc.	Lower Price Target	Buy	$20.00 -> $19.00

(Data available from 9/28/2014 forward)

Earnings History for Galmed Pharmaceuticals (NASDAQ:GLMD)

Date	Quarter	Consensus Estimate	Actual EPS	Release Link	Conference Call
11/7/2016
8/3/2016	Q216	($0.35)	($0.39)	View	N/A
5/16/2016	Q116	($0.33)	($0.36)	View	Listen
3/22/2016	Q415	($0.28)	($0.29)	View	Listen
11/9/2015	Q315	($0.29)	($0.23)	View	N/A
8/13/2015	Q215	($0.28)	($0.21)	View	Listen
5/13/2015	Q1	($0.26)	($0.22)	View	Listen
3/31/2015		($0.36)	($0.15)	View	N/A
11/12/2014	Q314	($0.37)	($0.62)	View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Galmed Pharmaceuticals (NASDAQ:GLMD)

Current Year EPS Consensus Estimate: $-1.51 EPS
Next Year EPS Consensus Estimate: $-1.26 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	2	($0.32)	($0.32)	($0.32)
Q2 2016	3	($0.41)	($0.26)	($0.35)
Q3 2016	3	($0.44)	($0.28)	($0.37)
Q4 2016	3	($0.39)	($0.30)	($0.34)
Q1 2017	1	($0.29)	($0.29)	($0.29)
Q2 2017	1	($0.29)	($0.29)	($0.29)
Q3 2017	1	($0.21)	($0.21)	($0.21)
Q4 2017	1	($0.21)	($0.21)	($0.21)

(Data provided by Zacks Investment Research)

Dividend History for Galmed Pharmaceuticals (NASDAQ:GLMD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Galmed Pharmaceuticals (NASDAQ:GLMD)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Galmed Pharmaceuticals (NASDAQ:GLMD)

Date	Headline
	Galmed Pharmaceuticals and the University of California, San Diego Enter into an Investigator-Initiated … (NASDAQ:GLMD) finance.yahoo.com - September 23 at 4:57 PM
	Galmed Pharmaceuticals and the University of California, San Diego Enter into an Investigator-Initiated Clinical Trial Agreem... (NASDAQ:GLMD) ih.advfn.com - September 23 at 4:57 PM
	Eye Catching Stocks Gaining Limelight: Microsoft (NASDAQ:MSFT), Galmed Pharmaceuticals (NASDAQ:GLMD ... - Street Wise Report (press release) (blog) (NASDAQ:GLMD) streetwisereport.com - September 23 at 10:14 AM
	Galmed Pharma (GLMD), UCSD Enter Collaboration to Assess Aramchol in Juvenile Population - StreetInsider.com (NASDAQ:GLMD) www.streetinsider.com - September 22 at 5:20 PM
	Galmed Pharmaceuticals Ltd Declines Again; Strong Momentum for Sellers - Post News (NASDAQ:GLMD) www.kentuckypostnews.com - September 21 at 5:43 PM
	Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) Receives Consensus Rating of “Buy” from Analysts - DailyQuint (NASDAQ:GLMD) dailyquint.com - September 21 at 5:43 PM
	Analysts Weigh in on Two Rising Biotech Stocks: Tobira Therapeutics Inc (TBRA) and Galmed Pharmaceuticals Ltd ... - Smarter Analyst (NASDAQ:GLMD) www.smarteranalyst.com - September 21 at 5:43 PM
	What are Analysts Expecting for Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Earnings? - Frisco Fastball (NASDAQ:GLMD) friscofastball.com - September 21 at 5:43 PM
	Earnings Take Center Stage; Analysts Weighing in on Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) - Frisco Fastball (NASDAQ:GLMD) friscofastball.com - September 14 at 5:19 PM
	Galmed Pharma (GLMD) Names Dr. Liat Hayardeny as Chief Scientific Officer (NASDAQ:GLMD) www.streetinsider.com - September 9 at 9:58 AM
	Shares Gapping Up Before the Open: Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) - Post News (NASDAQ:GLMD) www.kentuckypostnews.com - September 8 at 9:05 AM
	Placing Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Shares Under the Microscope - Post News (NASDAQ:GLMD) www.kentuckypostnews.com - September 8 at 9:05 AM
	Galmed Pharma (GLMD) Names Dr. Liat Hayardeny as Chief Scientific Officer - StreetInsider.com (NASDAQ:GLMD) www.streetinsider.com - September 8 at 9:05 AM
	Galmed Pharmaceuticals Announces the Appointment of Dr. Liat Hayardeny, Ph.D. MBA, as Chief Scientific Officer (NASDAQ:GLMD) www.publicnow.com - September 8 at 9:05 AM
	Shares Gapping Higher Pre-Market: Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) - Post News (NASDAQ:GLMD) www.kentuckypostnews.com - September 3 at 9:52 AM
	Shares Climbing Higher in Session: Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) - Post News (NASDAQ:GLMD) www.kentuckypostnews.com - August 29 at 5:08 PM
	Sell-side & Crowd View on Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) - Post News (NASDAQ:GLMD) www.kentuckypostnews.com - August 25 at 10:16 AM
	Earnings According to Analysts for Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD)? - Post News (NASDAQ:GLMD) www.kentuckypostnews.com - August 18 at 5:14 PM
	Crowd is Weighing in on Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) - Post News (NASDAQ:GLMD) www.kentuckypostnews.com - August 18 at 8:12 AM
	Galmed Pharmaceuticals (GLMD) Q2-2016 Results (NASDAQ:GLMD) www.bioportfolio.com - August 17 at 8:16 AM
	Galmed Pharmaceuticals reports 2Q loss (NASDAQ:GLMD) finance.yahoo.com - August 4 at 8:08 AM
	Galmed Pharmaceuticals' (GLMD) CEO Allen Baharaff on Q2 2016 Results - Earnings Call Transcript (NASDAQ:GLMD) seekingalpha.com - August 4 at 8:08 AM
	Galmed Pharma (GLMD) Names Ran Oren as Chief Medical Officer - StreetInsider.com (NASDAQ:GLMD) www.streetinsider.com - August 3 at 8:12 AM
	Galmed Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update (NASDAQ:GLMD) finance.yahoo.com - August 3 at 8:12 AM
	Maxim Group announced (NASDAQ:GLMD) Galmed Pharmaceuticals Ltd, bumping down its target price to $9 earlier today (NASDAQ:GLMD) breakingfinancenews.com - August 1 at 5:07 PM
	[$$] Galmed Could Double, Even With Reduced Outlook (NASDAQ:GLMD) www.barrons.com - August 1 at 5:07 PM
	Galmed Pharmaceuticals Announces the Appointment of Professor Ran Oren, M.D., as Chief Medical Officer (NASDAQ:GLMD) www.publicnow.com - August 1 at 8:11 AM
	8:09 am Galmed Pharma names Ran Oren, M.D., as Chief Medical Officer (NASDAQ:GLMD) finance.yahoo.com - August 1 at 8:09 AM
	Galmed Pharmaceuticals and SAMIL Pharm Sign a License Agreement for the Commercialization of Aramchol™ in Korea (NASDAQ:GLMD) finance.yahoo.com - July 28 at 8:00 AM
	Galmed Pharmaceuticals Second Quarter 2016 Conference Call and Webcast Scheduled for Wednesday, August 3rd, 2016 (NASDAQ:GLMD) www.publicnow.com - July 27 at 8:48 AM
	Earnings Focus and Crowd Sourced Sentiment Review for Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) - TGP (NASDAQ:GLMD) telanaganapress.com - July 22 at 8:09 AM
	Tracking Analyst Ratings and Target Projections for: Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) - Press Telegraph (NASDAQ:GLMD) presstelegraph.com - July 21 at 5:26 PM
	Galmed Pharmaceuticals Limited Ord (NASDAQ:GLMD) Sellers Increased By 8.56% Their Shorts - Consumer Eagle (NASDAQ:GLMD) www.consumereagle.com - July 21 at 5:26 PM
	Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:GLMD) www.engelwooddaily.com - July 20 at 8:07 AM
	Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Increased 2.56%: Cognizant Technology Solutions Corporation ... - KC Register (NASDAQ:GLMD) www.kcregister.com - July 18 at 5:28 PM
	Trading Performance and Target Watch for Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) - Press Telegraph (NASDAQ:GLMD) presstelegraph.com - July 18 at 5:28 PM
	Were Analysts Bearish Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) This Week? - Consumer Eagle (NASDAQ:GLMD) www.consumereagle.com - July 18 at 5:28 PM
	Could Galmed Pharmaceuticals Ltd Go Down? The Stock Formed Bearish Double Bottom Chart Pattern - Consumer Eagle (NASDAQ:GLMD) www.consumereagle.com - July 14 at 5:21 PM
	Crowd Rating and Earnings Recap for Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) - Telanagana Press (NASDAQ:GLMD) telanaganapress.com - July 14 at 5:21 PM
	Brokers Issue Average Price Target Of 19.00 On Galmed Pharmaceuticals Ltd. (GLMD) - Fiscal Standard (NASDAQ:GLMD) www.fiscalstandard.com - July 14 at 5:21 PM
	Galmed Pharmaceuticals Ltd. (GLMD) Updated Price Targets - FTSE News (NASDAQ:GLMD) www.ftsenews.co.uk - July 14 at 5:21 PM
	Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:GLMD) www.engelwooddaily.com - July 13 at 8:06 AM
	Are Analysts Bearish Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) After Last Week? - Press Telegraph (NASDAQ:GLMD) presstelegraph.com - July 11 at 9:59 AM
	Broker Outlook For Galmed Pharmaceuticals Ltd. (GLMD) - Fiscal Standard (NASDAQ:GLMD) www.fiscalstandard.com - July 7 at 8:03 AM
	Broker Outlook For The Week Ahead Galmed Pharmaceuticals Ltd. (GLMD) - Fiscal Standard (NASDAQ:GLMD) www.fiscalstandard.com - July 5 at 9:56 AM
	Does This Provide a Reason to Sell Galmed Pharmaceuticals Ltd? The Stock Has Formed Bearish Double Bottom - Press Telegraph (NASDAQ:GLMD) presstelegraph.com - July 4 at 10:09 AM
	Galmed Pharma (GLMD), Weizmann Institute of Science Enter Research Collaboration - StreetInsider.com (NASDAQ:GLMD) www.streetinsider.com - July 1 at 8:01 AM
	Galmed Pharma (GLMD), Weizmann Institute of Science Enter Research Collaboration (NASDAQ:GLMD) www.streetinsider.com - June 30 at 5:31 PM
	Galmed Pharmaceuticals and Weizmann Institute of Science to enter a research collaboration agreement to assess Aramchol™ effects on microbiome (NASDAQ:GLMD) www.publicnow.com - June 30 at 8:21 AM
	Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Earnings Glance and Target Price Review - Engelwood Daily (NASDAQ:GLMD) www.engelwooddaily.com - June 28 at 10:10 PM